Meribank Biotech Co., Ltd
Meribank Biotech Co., Ltd researches, develops, manufactures, and stores mesenchymal stem cells in Taiwan. The company engages in the detection, extraction, cryopreservation, archiving, and storage of umbilical cord blood, placental and umbilical cord mesenchymal stem cells, adult peripheral blood stem cells, and immune cells. It also provides cell cryopreservation services. The company was found… Read more
Meribank Biotech Co., Ltd (4724) - Net Assets
Latest net assets as of June 2025: NT$1.21 Billion TWD
Based on the latest financial reports, Meribank Biotech Co., Ltd (4724) has net assets worth NT$1.21 Billion TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$2.83 Billion) and total liabilities (NT$1.62 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$1.21 Billion |
| % of Total Assets | 42.77% |
| Annual Growth Rate | 22.88% |
| 5-Year Change | 218.16% |
| 10-Year Change | N/A |
| Growth Volatility | 38.68 |
Meribank Biotech Co., Ltd - Net Assets Trend (2019–2024)
This chart illustrates how Meribank Biotech Co., Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Meribank Biotech Co., Ltd (2019–2024)
The table below shows the annual net assets of Meribank Biotech Co., Ltd from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.22 Billion | +81.38% |
| 2023-12-31 | NT$671.20 Million | +41.66% |
| 2022-12-31 | NT$473.79 Million | -19.15% |
| 2021-12-31 | NT$586.05 Million | +53.16% |
| 2020-12-31 | NT$382.64 Million | -11.91% |
| 2019-12-31 | NT$434.36 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Meribank Biotech Co., Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9254000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | NT$879.76 Million | 72.97% |
| Other Comprehensive Income | NT$-11.62 Million | -0.96% |
| Other Components | NT$710.82 Million | 58.95% |
| Total Equity | NT$1.21 Billion | 100.00% |
Meribank Biotech Co., Ltd Competitors by Market Cap
The table below lists competitors of Meribank Biotech Co., Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Black Iron Inc
PINK:BKIRF
|
$17.66 Million |
|
Apollo Food Holdings Bhd
KLSE:6432
|
$17.67 Million |
|
Fathom Holdings Inc
NASDAQ:FTHM
|
$17.67 Million |
|
Okong Corporation
KQ:045060
|
$17.68 Million |
|
Sukhjit Starch & Chemicals Limited
NSE:SUKHJITS
|
$17.65 Million |
|
Modulight Oyj
HE:MODU
|
$17.65 Million |
|
Cytosorbents Corporation
F:HQE1
|
$17.65 Million |
|
Jeil Technos Co.Ltd
KQ:038010
|
$17.64 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Meribank Biotech Co., Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 661,732,000 to 1,205,728,000, a change of 543,996,000 (82.2%).
- Net loss of 94,711,000 reduced equity.
- Other comprehensive income decreased equity by 2,584,999.
- Other factors increased equity by 641,291,999.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-94.71 Million | -7.86% |
| Other Comprehensive Income | NT$-2.58 Million | -0.21% |
| Other Changes | NT$641.29 Million | +53.19% |
| Total Change | NT$- | 82.21% |
Book Value vs Market Value Analysis
This analysis compares Meribank Biotech Co., Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.99x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.83x to 0.99x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | NT$8.20 | NT$15.00 | x |
| 2020-12-31 | NT$7.18 | NT$15.00 | x |
| 2021-12-31 | NT$9.61 | NT$15.00 | x |
| 2022-12-31 | NT$7.46 | NT$15.00 | x |
| 2023-12-31 | NT$10.51 | NT$15.00 | x |
| 2024-12-31 | NT$15.15 | NT$15.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Meribank Biotech Co., Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -7.86%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -25.85%
- • Asset Turnover: 0.14x
- • Equity Multiplier: 2.22x
- Recent ROE (-7.86%) is above the historical average (-15.57%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -13.79% | -37.22% | 0.23x | 1.60x | NT$-103.33 Million |
| 2020 | -14.23% | -28.01% | 0.27x | 1.91x | NT$-92.72 Million |
| 2021 | -16.93% | -60.83% | 0.17x | 1.62x | NT$-157.80 Million |
| 2022 | -21.68% | -56.70% | 0.21x | 1.80x | NT$-149.25 Million |
| 2023 | -18.94% | -53.49% | 0.22x | 1.60x | NT$-191.52 Million |
| 2024 | -7.86% | -25.85% | 0.14x | 2.22x | NT$-215.28 Million |
Industry Comparison
This section compares Meribank Biotech Co., Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,057,086,200
- Average return on equity (ROE) among peers: 8.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Meribank Biotech Co., Ltd (4724) | NT$1.21 Billion | -13.79% | 1.34x | $17.66 Million |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |